Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study
Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study
复制标题
DOI：
10.1016/s2214-109x(18)30306-1
复制
发表时间：
2018-09-01
影响因子：
34.3
通讯作者：
Lam, Carolyn S. P.
中科院分区：
文献类型：
--
作者：
Teng, Tiew-Hwa K.;Tromp, Jasper;Lam, Carolyn S. P.
背景
血管紧张素转换酶（ACE）抑制剂或血管紧张素II受体阻滞剂（ARB）、β受体阻滞剂以及盐皮质激素受体拮抗剂（MRA）已被证实有益，并被心力衰竭和射血分数降低（HFrEF）患者管理指南所推荐。我们旨在研究来自亚洲的首个关于指南指导的药物治疗处方模式的前瞻性多国数据，并分析其对预后的影响。
方法
在这项前瞻性多国的亚洲心力衰竭（ASIAN - HF）注册研究中（纳入来自亚洲11个国家的46个中心的患者），我们招募了年龄在18岁及以上、有症状性心力衰竭（C期，在过去6个月内至少有一次失代偿性心力衰竭发作，导致入院或在门诊接受治疗）以及左心室收缩功能障碍（射血分数<40%）的患者。
Background Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), beta blockers, and mineralocorticoid receptor antagonists (MRAs) are of proven benefit and are recommended by guidelines for management of patients with heart failure and reduced ejection fraction (HFrEF). We aimed to examine the first prospective multinational data from Asia on prescribing patterns of guideline-directed medical therapies and analyse its effect on outcomes.Methods In the prospective multinational ASIAN-HF registry (with enrolment from 46 centres in 11 countries in Asia), we enrolled patients aged 18 years or older, with symptomatic heart failure (stage C, with at least one episode of decompensated heart failure in the past 6 months that resulted in admission to hospital or was treated in an outpatient clinic) and left ventricular systolic dysfunction (ejection fraction